Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 77Nivolumab 64Ipilimumab 40Specimen Handling 33Magnetic Resonance Spectroscopy 27Cyclophosphamide 26Biopsy 20cemiplimab 16fludarabine 14Radiosurgery 14relatlimab 13CTLA-4 Antigen 13binimetinib 12Opdualag 12trametinib 11fludarabine phosphate 11avelumab 9Immunoglobulin G 9Blood Specimen Collection 9lifileucel 8dabrafenib 8atezolizumab 8Radiotherapy 8Disulfides 8encorafenib 7aldesleukin 7X-Rays 7Paclitaxel 7Standard of Care 6Interleukin-2 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
bintrafusp alfa protein, human × Dermatologic × 90 days × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡